

Performance (consolidated)

(¥ million)

	2016 (JGAAP)	2017 (JGAAP)	2018 (JGAAP)	2019 (JGAAP)	2020 (IFRS)	2021 (IFRS)	2022 (IFRS) (estimated)
Revenue	98,781	101,448	114,716	116,637	121,859	137,484	134,000
Operating profit	15,280	17,079	20,644	21,668	27,202	32,948	27,000
Profit before tax	16,244	17,451	21,540	22,442	27,608	33,301	27,500
Profit attributable to owners of parent	11,749	12,953	16,302	16,866	19,540	24,986	21,500

(¥ million)

Brand name	Active Ingredient	Indications	Launch Date	Sales 2020 (IFRS)	Sales 2021 (IFRS)	Sales 2022 (IFRS)		
						Apr-Jun	Apr-Sep (estimated)	Annual (estimated)
Vidaza	azacitidine	myelodysplastic syndrome/ acute myeloid leukemia	Mar-2011/ Mar-2021	15,350	18,338	4,800	7,800	12,400
Viltepso	viltolarsen	Duchenne muscular dystrophy	Japan May-2020 U.S. Aug-2020	2,387	7,750	3,193	5,900	13,000
(Japan)				(1,953)	(4,059)	(1,054)	(2,200)	(4,750)
(U.S.)				(434)	(3,691)	(2,139)	(3,700)	(8,250)
Upravi	selexipag	pulmonary arterial hypertension/ chronic thromboembolic pulmonary hypertension	Nov-2016/ Aug-2021	6,804	8,400	2,367	4,500	9,800
Tramal, Onetram	tramadol hydrochloride	cancer pain, chronic pain	Sep-2010	6,906	6,770	1,674	2,700	5,000
Gazyva	obinutuzumab	CD20-positive follicular lymphoma	Aug-2018	5,312	5,300	1,333	2,700	5,800
Zalutia	tadalafil	urinary disorder caused by benign prostatic hyperplasia	Apr-2014	6,743	4,106	771	1,300	2,300
Cialis	tadalafil	erectile dysfunction	Jul-2009	2,677	2,532	754	1,250	2,600
Adcirca	tadalafil	pulmonary arterial hypertension	Dec-2009	5,474	4,563	742	1,400	2,500
Defitelio	defibrotide sodium	sinusoidal obstruction syndrome	Sep-2019	1,970	2,128	594	1,000	2,300
Erizas	dexamethasone cipeclate	allergic rhinitis	Dec-2009	2,444	2,330	385	700	2,400
Profit in co-promotion				8,442	8,934	2,603	4,600	9,500
Revenues from the licensing of industrial property rights				24,338	33,207	6,903	14,600	29,800
Pharmaceuticals				106,478	120,650	30,407	57,400	115,000
Functional Food				15,380	16,834	5,211	9,600	19,000
Revenue				121,859	137,484	35,619	67,000	134,000